JP2018527924A5 - - Google Patents
Info
- Publication number
- JP2018527924A5 JP2018527924A5 JP2018509904A JP2018509904A JP2018527924A5 JP 2018527924 A5 JP2018527924 A5 JP 2018527924A5 JP 2018509904 A JP2018509904 A JP 2018509904A JP 2018509904 A JP2018509904 A JP 2018509904A JP 2018527924 A5 JP2018527924 A5 JP 2018527924A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding protein
- binding fragment
- seq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 102
- 108091000831 antigen binding proteins Proteins 0.000 claims description 102
- 239000012634 fragment Substances 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 52
- 102000036639 antigens Human genes 0.000 claims description 52
- 108091007433 antigens Proteins 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 241000588748 Klebsiella Species 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 206010061259 Klebsiella infection Diseases 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 238000012575 bio-layer interferometry Methods 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 206010011409 Cross infection Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 208000032376 Lung infection Diseases 0.000 claims description 2
- 208000006816 Neonatal Sepsis Diseases 0.000 claims description 2
- 206010029803 Nosocomial infection Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 206010048038 Wound infection Diseases 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 206010014801 endophthalmitis Diseases 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000002956 necrotizing effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- 241001534216 Klebsiella granulomatis Species 0.000 claims 1
- 241000588749 Klebsiella oxytoca Species 0.000 claims 1
- 206010024652 Liver abscess Diseases 0.000 claims 1
- 241000588746 Raoultella planticola Species 0.000 claims 1
- -1 aminoglycosides Chemical class 0.000 claims 1
- 229940041011 carbapenems Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000012004 kinetic exclusion assay Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 10
- 241000588747 Klebsiella pneumoniae Species 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 101100446843 Klebsiella pneumoniae mrkA gene Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208975P | 2015-08-24 | 2015-08-24 | |
| US62/208,975 | 2015-08-24 | ||
| US201562238828P | 2015-10-08 | 2015-10-08 | |
| US62/238,828 | 2015-10-08 | ||
| PCT/US2016/048221 WO2017035154A1 (en) | 2015-08-24 | 2016-08-23 | Mrka polypeptides, antibodies, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527924A JP2018527924A (ja) | 2018-09-27 |
| JP2018527924A5 true JP2018527924A5 (enExample) | 2019-10-03 |
Family
ID=58100831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509904A Pending JP2018527924A (ja) | 2015-08-24 | 2016-08-23 | Ｍｒｋａポリペプチド、抗体、およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170073397A1 (enExample) |
| EP (1) | EP3341004A4 (enExample) |
| JP (1) | JP2018527924A (enExample) |
| KR (1) | KR20180042300A (enExample) |
| CN (1) | CN107921086A (enExample) |
| AU (1) | AU2016313653A1 (enExample) |
| BR (1) | BR112018003252A2 (enExample) |
| CA (1) | CA2995387A1 (enExample) |
| CL (1) | CL2018000357A1 (enExample) |
| CO (1) | CO2018001985A2 (enExample) |
| HK (1) | HK1252350A1 (enExample) |
| IL (1) | IL257434A (enExample) |
| MX (1) | MX2018001964A (enExample) |
| RU (1) | RU2018107056A (enExample) |
| TW (1) | TW201718626A (enExample) |
| WO (1) | WO2017035154A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900027XA (en) * | 2016-08-05 | 2019-02-27 | Medimmune Llc | Anti-o2 antibodies and uses thereof |
| WO2018075375A1 (en) | 2016-10-19 | 2018-04-26 | Medimmune, Llc | Anti-o1 antibodies and uses thereof |
| JP2020525540A (ja) | 2017-06-23 | 2020-08-27 | ノソコミアル ヴァクスィーン コーポレイション | 免疫原性組成物 |
| CN115838430A (zh) * | 2022-07-08 | 2023-03-24 | 中国人民解放军陆军军医大学 | 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用 |
| CN116813725B (zh) * | 2023-07-06 | 2025-11-04 | 深圳康泰生物制品股份有限公司 | 肺炎克雷伯菌的FimA的抗原表位肽及其应用 |
| CN119798389A (zh) * | 2024-12-12 | 2025-04-11 | 中国人民解放军军事科学院军事医学研究院 | 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| WO2001010386A2 (en) * | 1999-08-11 | 2001-02-15 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| US7041465B1 (en) * | 1999-08-11 | 2006-05-09 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| WO2005034733A2 (en) * | 2003-10-08 | 2005-04-21 | North Shore-Long Island Jewish Research Institute | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| EA018030B1 (ru) * | 2006-06-06 | 2013-05-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| EP2152731A2 (en) * | 2007-05-02 | 2010-02-17 | Intercell AG | Klebsiella antigens |
| GB0915403D0 (en) * | 2009-09-04 | 2009-10-07 | London School Hygiene & Tropical Medicine | Protein glycosylation |
| WO2011100700A2 (en) * | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| WO2012058334A1 (en) * | 2010-10-26 | 2012-05-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Morphology & protein specific reagents as diagnostics for neurodegenerative diseases |
| SMT202000542T1 (it) * | 2011-11-07 | 2020-11-10 | Medimmune Ltd | Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas |
-
2016
- 2016-08-23 MX MX2018001964A patent/MX2018001964A/es unknown
- 2016-08-23 HK HK18111635.8A patent/HK1252350A1/zh unknown
- 2016-08-23 TW TW105126946A patent/TW201718626A/zh unknown
- 2016-08-23 US US15/244,960 patent/US20170073397A1/en not_active Abandoned
- 2016-08-23 AU AU2016313653A patent/AU2016313653A1/en not_active Abandoned
- 2016-08-23 KR KR1020187007376A patent/KR20180042300A/ko not_active Withdrawn
- 2016-08-23 WO PCT/US2016/048221 patent/WO2017035154A1/en not_active Ceased
- 2016-08-23 BR BR112018003252A patent/BR112018003252A2/pt not_active Application Discontinuation
- 2016-08-23 RU RU2018107056A patent/RU2018107056A/ru not_active Application Discontinuation
- 2016-08-23 CA CA2995387A patent/CA2995387A1/en not_active Abandoned
- 2016-08-23 CN CN201680047771.3A patent/CN107921086A/zh active Pending
- 2016-08-23 EP EP16839995.4A patent/EP3341004A4/en not_active Withdrawn
- 2016-08-23 JP JP2018509904A patent/JP2018527924A/ja active Pending
-
2018
- 2018-02-08 CL CL2018000357A patent/CL2018000357A1/es unknown
- 2018-02-08 IL IL257434A patent/IL257434A/en unknown
- 2018-02-23 CO CONC2018/0001985A patent/CO2018001985A2/es unknown
- 2018-03-29 US US15/940,344 patent/US20190062411A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527924A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP2020500005A5 (enExample) | ||
| JP7160484B2 (ja) | 抗ｏ１抗体およびその使用 | |
| RU2018107056A (ru) | Полипептиды mrka, антитела к ним и пути их применения | |
| CN114729033B (zh) | 抗α-溶血素的抗体及其应用 | |
| ES2426093T3 (es) | Anticuerpo dirigido contra PcrV | |
| JP2020522280A5 (enExample) | ||
| CN109689090B (zh) | 抗o2抗体及其用途 | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| CN111333723A (zh) | 针对狂犬病病毒g蛋白的单克隆抗体及其用途 | |
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| JP2017521054A5 (enExample) | ||
| JP2016520595A5 (enExample) | ||
| IL278323B1 (en) | Antibodies directed against glycoprotein IV | |
| CN114685653B (zh) | 抗新冠病毒受体结合区域表位中和抗体及其应用 | |
| EP4608864A1 (en) | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases | |
| KR20220148198A (ko) | 항-bcma 항체, 이의 약학 조성물 및 응용 | |
| CN111356702A (zh) | 抗pd-l1抗体及其抗原结合片段 | |
| RU2022107387A (ru) | Межвидовые антитела к латентному tgf-бeta 1 и способы их применения | |
| HK40009426A (en) | Anti-o1 antibodies and uses thereof | |
| JPWO2023011338A5 (enExample) | ||
| HK1248576A1 (en) | Mrka polypeptides, antibodies, and uses thereof | |
| HK40007861A (en) | Anti-o2 antibodies and uses thereof | |
| NZ739360A (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof |